Cargando…

Efficacy of Eribulin in Soft Tissue Sarcomas

Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated advanced Liposarcoma and Leiomyosarcoma demonstrated superiority of eribulin to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Edward, Jones, Robin L., Huang, Paul, Digklia, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014307/ https://www.ncbi.nlm.nih.gov/pubmed/35444542 http://dx.doi.org/10.3389/fphar.2022.869754

Ejemplares similares

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival
por: Thomas, Colin, et al.
Publicado: (2016)

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021)

The Role of Trabectedin in Soft Tissue Sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2022)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma(†)
por: Kawai, Akira, et al.
Publicado: (2017)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment
por: Takada, Kohichi, et al.
Publicado: (2019)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
por: López-Álvarez, María, et al.
Publicado: (2022)

Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023)

Chemotherapeutic drugs for soft tissue sarcomas: a review
por: Tian, Zhichao, et al.
Publicado: (2023)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
por: Merry, Eve, et al.
Publicado: (2021)

Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?
por: Arthur, Amani, et al.
Publicado: (2022)

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
por: Kawai, Akira, et al.
Publicado: (2022)

The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling
por: Pankova, Valeriya, et al.
Publicado: (2021)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

Deciphering the role of NETosis-related signatures in the prognosis and immunotherapy of soft-tissue sarcoma using machine learning
por: Qi, Lin, et al.
Publicado: (2023)

Pyroptosis-related genes prognostic model for predicting targeted therapy and immunotherapy response in soft tissue sarcoma
por: Liu, Mengmeng, et al.
Publicado: (2023)

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
por: Shimada, Eijiro, et al.
Publicado: (2021)

Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
por: Kerrison, William G. J., et al.
Publicado: (2022)

Optimal Delivery of Follow-Up Care Following Treatment for Adults Treated for Ewing Sarcoma
por: Digklia, Antonia, et al.
Publicado: (2023)

Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas
por: Napolitano, Andrea, et al.
Publicado: (2021)

Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma
por: Qi, Lin, et al.
Publicado: (2023)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas
por: Cassandri, Matteo, et al.
Publicado: (2020)

Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
por: Escudero, Javier, et al.
Publicado: (2021)

Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures
por: Degrauwe, Nils, et al.
Publicado: (2019)

The proteomic landscape of soft tissue sarcomas
por: Burns, Jessica, et al.
Publicado: (2023)

Integration analysis of senescence-related genes to predict prognosis and immunotherapy response in soft-tissue sarcoma: evidence based on machine learning and experiments
por: Qi, Lin, et al.
Publicado: (2023)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Efficacy and Safety of Iclaprim for the Treatment of Skin Structures and Soft Tissue Infections: A Methodological Framework
por: Wang, Lian, et al.
Publicado: (2022)

Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas
por: Chadha, Madhumeeta, et al.
Publicado: (2022)

2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma
por: Frezza, Anna Maria, et al.
Publicado: (2018)

Cancer Stem Cells in Soft-Tissue Sarcomas
por: Martínez-Delgado, Paula, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d7lbino108o7ae4vk3854qmg04